Bright Minds Ownership
| DRUG Stock | USD 39.18 1.07 2.81% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bright |
Bright Stock Ownership Analysis
About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.63. Bright Minds Biosciences had not issued any dividends in recent years. The entity had 1:5 split on the 14th of July 2023. Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT medicines to improve the lives of patients with severe and life-altering diseases. The company was incorporated in 2019 and is headquartered in Vancouver, Canada. Bright Minds is traded on NASDAQ Exchange in the United States. To learn more about Bright Minds Biosciences call Ian McDonald at 647 407 2515 or check out https://brightmindsbio.com.Besides selling stocks to institutional investors, Bright Minds also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bright Minds' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bright Minds' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bright Minds Quarterly Liabilities And Stockholders Equity |
|
About 27.0% of Bright Minds Biosciences are currently held by insiders. Unlike Bright Minds' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bright Minds' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bright Minds' insider trades
Bright Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bright Minds is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bright Minds Biosciences backward and forwards among themselves. Bright Minds' institutional investor refers to the entity that pools money to purchase Bright Minds' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisorshares Investments, Llc | 2024-09-30 | 182.4 K | Jane Street Group Llc | 2024-06-30 | 10.9 K | Royal Bank Of Canada | 2024-06-30 | 510 | Aspire Private Capital, Llc | 2024-09-30 | 100.0 | Blackrock Inc | 2024-06-30 | 1.0 |
Bright Minds Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bright Minds insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bright Minds' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bright Minds insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cormorant Asset Management, Lp over three weeks ago Acquisition by Cormorant Asset Management, Lp of 184331 shares of Bright Minds at 21.7 subject to Rule 16b-3 | ||
Cormorant Asset Management, Lp over a month ago Insider Trading |
Bright Minds Outstanding Bonds
Bright Minds issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bright Minds Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bright bonds can be classified according to their maturity, which is the date when Bright Minds Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Bright Minds Corporate Filings
6K | 21st of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 19th of November 2024 Other Reports | ViewVerify | |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 6th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.